Schistosoma-Salmonella co-infection in Africa: Epidemiology, biological mechanisms, and antimicrobial resistance: A systematic review and meta analysis
- 1Department of Medical Laboratory Science, College of Medicine and Health Sciences, Adigrat, Ethiopia.
- 2Department of Medical Parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Abstract
Schistosomiasis and salmonellosis are major public health problems in Africa, contribute substantially to morbidity. Schistosoma-Salmonella co-infection is a neglected and overlooked health condition with important clinical and public health implications. Therefore, we conducted a systematic review and meta-analysis to synthesize evidence on the epidemiology, biological mechanisms, and antimicrobial resistance of Schistosoma-Salmonella co-infection in Africa. A systematic review and Meta-analysis were conducted following the PRISMA framework. The pooled prevalence of co-infection was estimated using a random effects model, with at 95% confidence intervals. Between studies heterogeneity was assessed using Cochran’s Q test and the I2 statistic. Subgroup analyses were performed according to Schistosoma species and country to explore potential source of heterogeneity. This systematic review found that the pooled prevalence of Schistosoma-Salmonella co-infection in Africa was 9%. Species specific pooled prevalence was 4% for Schistosoma mansoni-Salmonella co-infection and 12% for Schistosoma hematobium-Salmonella co-infection. Country based subgroup analysis showed prevalence of Schistosoma mansoni-Salmonella co-infection of 2% in Ethiopia, 9% in Sudan, 2% in Democratic republic of Congo and 4% in Nigeria, while Schistosoma hematobium-Salmonella co-infection prevalence were 0%, 25%, and 8% in Ethiopia, Sudan, and Nigeria respectively. Schistosoma-Salmonella co-infection is driven by immune modulation, tissue pathology, and parasite bacterium interactions that support persistent infection and compromise therapeutic efficacy, thereby contributing to treatment failure and the emergence of antimicrobial resistance. Schistosoma-Salmonella co-infection represents an important and under-recognized public health concern in Africa, with a pooled prevalence of 9%. The findings demonstrate notable variation in co-infection prevalence across Schistosoma species and geographical settings, with higher rates observed among Schistosoma haematobium compared with Schistosoma mansoni. Strengthened surveillance systems, improving early diagnosis, and implementing integrated control strategies are essential to reduce the burden and enhance clinical management of this neglected co-infection in Africa.
Related
- Genomic epidemiology of multidrug-resistant and non-multidrug-resistant clinical Salmonella enterica isolates in Guangdong, China
- Phylogeographical structure and genetic introgression in Salmonella enterica serotype Napoli: a genomic epidemiology study
- Ecology and epidemiology of multidrug resistance Salmonella in fruit Bats and shared water sources in Bangladesh
- A Salmonella -specific protein enhances the antimicrobial peptide response of the PhoPQ two-component system
- Antimicrobial-resistant Salmonella and Escherichia coli in fresh vegetables from Ouagadougou, Burkina Faso: Prevalence, β-lactamase genes, and food safety implications
BibTeX
@article{berhe2026schistosomasalmonella,
title = {{Schistosoma-Salmonella co-infection in Africa: Epidemiology, biological mechanisms, and antimicrobial resistance: A systematic review and meta analysis}},
author = {Brhane Berhe and Hadush Negash and Tesfay Abadi and Getachew Belay and Merhawi Alemu and Aberham Abere and Haftom Legese and Abel Deres},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0359975},
url = {https://doi.org/10.1371/journal.pone.0359975},
note = {CC BY},
}
RIS
TY - JOUR
TI - Schistosoma-Salmonella co-infection in Africa: Epidemiology, biological mechanisms, and antimicrobial resistance: A systematic review and meta analysis
AU - Brhane Berhe
AU - Hadush Negash
AU - Tesfay Abadi
AU - Getachew Belay
AU - Merhawi Alemu
AU - Aberham Abere
AU - Haftom Legese
AU - Abel Deres
PY - 2026
DA - 2026/10/29
JO - PLOS One
DO - 10.1371/journal.pone.0359975
UR - https://doi.org/10.1371/journal.pone.0359975
AB - Schistosomiasis and salmonellosis are major public health problems in Africa, contribute substantially to morbidity. Schistosoma-Salmonella co-infection is a neglected and overlooked health condition with important clinical and public health implications. Therefore, we conducted a systematic review and meta-analysis to synthesize evidence on the epidemiology, biological mechanisms, and antimicrobial resistance of Schistosoma-Salmonella co-infection in Africa. A systematic review and Meta-analysis were conducted following the PRISMA framework. The pooled prevalence of co-infection was estimated using a random effects model, with at 95% confidence intervals. Between studies heterogeneity was assessed using Cochran’s Q test and the I2 statistic. Subgroup analyses were performed according to Schistosoma species and country to explore potential source of heterogeneity. This systematic review found that the pooled prevalence of Schistosoma-Salmonella co-infection in Africa was 9%. Species specific pooled prevalence was 4% for Schistosoma mansoni-Salmonella co-infection and 12% for Schistosoma hematobium-Salmonella co-infection. Country based subgroup analysis showed prevalence of Schistosoma mansoni-Salmonella co-infection of 2% in Ethiopia, 9% in Sudan, 2% in Democratic republic of Congo and 4% in Nigeria, while Schistosoma hematobium-Salmonella co-infection prevalence were 0%, 25%, and 8% in Ethiopia, Sudan, and Nigeria respectively. Schistosoma-Salmonella co-infection is driven by immune modulation, tissue pathology, and parasite bacterium interactions that support persistent infection and compromise therapeutic efficacy, thereby contributing to treatment failure and the emergence of antimicrobial resistance. Schistosoma-Salmonella co-infection represents an important and under-recognized public health concern in Africa, with a pooled prevalence of 9%. The findings demonstrate notable variation in co-infection prevalence across Schistosoma species and geographical settings, with higher rates observed among Schistosoma haematobium compared with Schistosoma mansoni. Strengthened surveillance systems, improving early diagnosis, and implementing integrated control strategies are essential to reduce the burden and enhance clinical management of this neglected co-infection in Africa.
SN - 1932-6203
ER -